COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher's Stone?

Theano PenlioglouStella PapachristouNikoloas Papanas

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2020)

Corona virus infectious disease (COVID-19) is a new pandemic. In subjects with diabetes mellitus, infection may be more frequent and severe. We discuss the potential contribution of two traditional oral antidiabetic agents, metformin and pioglitazone, to the improvement of liver injury in COVID-19. Clearly, further experience is needed to shed light on these hypotheses.

Keyphrases

coronavirus disease
sars cov
liver injury
drug induced
infectious diseases
respiratory syndrome coronavirus
type diabetes
early onset
risk assessment
human health
metabolic syndrome
skeletal muscle